Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.64 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.64 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.64 |
| ▸ | GABRP | O00591 | 3/20 | 0.48 |
| ▸ | GABRD | O14764 | 3/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.48 |
| ▸ | GABRE | P78334 | 3/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14215423 | 0.84 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29382152 | 0.84 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7951942 | 0.84 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29521776 | 0.84 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL7377690 | 0.84 | ADRA1A (0.74) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL43933 | 0.84 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| Bromazepam SCHEMBL29366892 | 0.84 | ADRA1A (1.00) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL11837680 | 0.82 | ADRA1A (0.51) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL11603293 | 0.81 | ADRA1A (0.69) | ADRA1AGABRA1GABRA5GABRA3GABRA2 | |
| SCHEMBL13501729 | 0.81 | GABRA1 (0.58) | ADRA1AGABRA1GABRA5GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | claimed |
| US-20020137738-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | WU JING (US) | 2002-09-26 | — | — | US | claimed |
| CN-1242007-A | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising such compounds, and methods of inhibiting beta amyloid peptide release and/or its synthesis using such compounds | ELAND PHARMACEUTICAL CORP (US) | 2000-01-19 | — | — | CN | claimed |
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-3180326-B1 | BENZODIAZEPINE DERIVATIVES AS CCK2/GASTRIN RECEPTOR ANTAGONISTS | TRIO MEDICINES LTD (GB) | 2019-10-23 | — | — | EP | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| CN-1399634-A | Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production | BRISTOL MYERS SQUIBB PHARMA IN (US) | 2003-02-26 | — | — | CN | disclosed |
| EP-1089980-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0628033-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137738-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | ADRA1A 3037/4885GABRA1 1823/4885GABRA5 1660/4885 |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | GABRA3, GABRA2, GABRA1 | ADRA1A 145/4885GABRA1 3/4885GABRA5 6/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | ADRA1A 145/4885GABRA1 3/4885GABRA5 6/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | ADRA1A 528/4885GABRA1 5/4885GABRA5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.